Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by M.D. Anderson Cancer Center
Sponsor:
Collaborators:
Bristol-Myers Squibb
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01585194
First received: April 23, 2012
Last updated: October 4, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: November 2018 (Final data collection date for primary outcome measure)